Natural Capsules Q4 FY26 Revenue Rs 58.45 Cr, FY26 PAT (Rs 24.66 Cr)
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 28 May 2026, 09:29 PM IST · BSE ID: c81cc509-14dc-4831-94ca-bad424a65aeb
View Original BSE Filing (PDF)
⚡ Quick Answer
Natural Capsules Ltd reported a Q4 FY26 revenue of Rs 58.45 Cr and a full year FY26 PAT loss of Rs 24.66 Cr. The company's standalone capsules business saw improved topline and profitability in Q4. An incremental HPMC line for double-zero capsules is ready for revenue generation in H2 FY27, and the API business began commercial sales in Q4 FY26.
💡
In Simple Terms
Natural Capsules announced its latest financial results, showing improved quarterly sales and progress in new business segments.
🤖 AI Summary
- Natural Capsules reported Q4 FY26 revenue of Rs 58.45 Cr and full year FY26 PAT of (Rs 24.66 Cr).
- Q4 FY26 standalone capsules business dispatches of approximately T6 crores drove topline and profitability.
- Incremental HPMC line for double-zero capsules is ready; revenue expected from H2 FY27, pending client approval.
- Commercial sales for the API business commenced in Q4 FY26.
- Subsidiary Natural Biogenex executed agreements with Fermbox Bio for advanced fermentation technology and manufacturing.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Q4 FY26 Revenue
Rs 58.45 Cr
30%
Q4 FY26 PAT
(X4.98 Cr)
(3,808%)
FY26 Revenue
Rs 187.20 Cr
1%
FY26 PAT
(X 24.66 Cr)
(4,095%)
🏢 How This Affects the Company
The commencement of API commercial sales and the readiness of the incremental HPMC line introduce new revenue streams. The collaboration with Fermbox Bio is expected to enhance fermentation-based CDMO capabilities.
Q4 FY26 revenue saw an increase to Rs 58.45 Cr, driven by deferred dispatches. Full year FY26 PAT was (Rs 24.66 Cr), reflecting a significant decline.
The Puducherry plant shutdown impacted prior quarter operations, with Q4 FY26 reflecting successful dispatches. The new HPMC line expands manufacturing capacity.
The current API business carries a lower margin profile, awaiting regulatory clearances for improved profitability geographies. Client approval in US markets for the new HPMC line is a dependency.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results disclosure.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with Q4 FY26 revenue at Rs 58.45 Cr and full year FY26 PAT at (Rs 24.66 Cr).
🔍
Management Signal
Management aims to scale API operations, drive higher profitability in the capsules business, and improve operational efficiency for FY27.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — monitor revenue contribution from new HPMC line.
Updates on client approvals for the HPMC line in US markets.
Progress on regulatory clearances for API business expansion into higher profitability geographies.
MEDIUM RISK
Significant Y-o-Y decline in full year PAT and reliance on future approvals for new revenue streams introduce financial risk.
💡 Investor Takeaway
Natural Capsules reported Q4 FY26 revenue of Rs 58.45 Cr, up 30% Y-o-Y, and full year FY26 PAT of (Rs 24.66 Cr), down (4,095%) Y-o-Y. The company announced the new HPMC line for capsules is ready, and API commercial sales commenced.
⚖️ Strengths & Concerns
✅ Positives
- Q4 FY26 revenue increased to Rs 58.45 Cr, reflecting a 55% Q-o-Q growth and 30% Y-o-Y growth, driven by successful dispatches.
- The incremental HPMC line for double-zero capsules is ready, with revenue anticipated from H2 FY27 subject to client approval.
⚠️ Concerns
- PAT for Q4 FY26 was (X4.98 Cr), a (1,056%) Q-o-Q decrease and (3,808%) Y-o-Y decrease.
- Full year FY26 PAT was (X 24.66 Cr), a (4,095%) Y-o-Y decrease, and EBITDAMARGINS were (0.83%).
📅 Company Track Record
Natural Capsules Limited was incorporated as a Public Limited Company in 1993. The company pioneered vegetarian capsule manufacturing in India and expanded operations to Pondicherry in 2003. It is currently foraying into API manufacturing through its subsidiary Natural Biogenex Private Limited.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Natural Capsules' revenue for Q4 FY26?
Natural Capsules reported a revenue of Rs 58.45 Cr for the quarter ended March 31, 2026.
What was Natural Capsules' Net Profit (PAT) for the full year FY26?
The Net Profit (PAT) for Natural Capsules for the year ended March 31, 2026, was a loss of Rs 24.66 Cr.
When will the HPMC line for double-zero capsules generate revenue?
The incremental HPMC line for double-zero capsules is ready for revenue generation in the second half of FY27 (H2 FY27).
When did Natural Capsules' API business commence commercial sales?
Commercial sales for Natural Capsules' API business commenced in Q4 FY26.
What agreements did Natural Biogenex sign?
Natural Biogenex signed agreements with Fermbox Bio for fermentation technology and manufacturing.
Questions based on this BSE filing only. For information purposes.